GBR 1302Alternative Names: GBR-1302; HER2xCD3 bispecific antibody - Glenmark
Latest Information Update: 09 Jan 2017
Price : *
At a glance
- Originator Glenmark Pharmaceuticals S.A.
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Cytotoxic T lymphocyte modulators; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 03 Jan 2017 US FDA approves IND application for GBR 1302 in HER2 positive cancer
- 04 Nov 2016 Pharmacodynamics data from preclinical studies in Cancer were presented at European Society of Medical Oncology Symposium (ESMO-2016)
- 01 May 2016 Phase-I clinical trials in HER2 positive Cancer in Germany (Parenteral) (NCT02829372)